Areas of Focus
- 药理学
- 肿瘤药理学
Work Experience
- 2013-10到2016-06 - 中国科学院上海药物研究所 - 副研究员
- 2013-07到2013-09 - 中国科学院上海药物研究所 - 助理研究员
- 2011-05到2013-06 - 中国科学院上海药物研究所 - 博士后
- 2008-10到2010-12 - 瑞典Karolinska医学院 - 联合培养博士
- 2007-09到2010-12 - 吉林大学 - 博士
- 2004-09到2007-06 - 吉林大学 - 硕士
- 2000-09到2004-06 - 吉林大学 - 学士
Academic Background & Achievements
- 2008-10到2010-12 联合培养博士: 瑞典Karolinska医学院
- 2007-09到2010-12 博士: 吉林大学
- 2004-09到2007-06 硕士: 吉林大学
- 2000-09到2004-06 学士: 吉林大学
Publications
- Design and development of a novel series of oral bivalent BET inhibitors with potent anticancer activities, 第9作者, 2022
- Discovery of a series of 1H-pyrrolo2,3-bpyridine compounds as potent TNIK inhibitors, 第4作者, 2021
- Novel bivalent BET inhibitor N2817 exhibits potent anticancer activity and inhibits TAF1, 第9作者, 2021
- A new BET inhibitor, 171, inhibits tumor growth through cell proliferation inhibition more than apoptosis induction, 第12作者, 2020
- Polymerase independent repression of FoxO1 transcription by sequence-specific PARP1 binding to FoxO1 promoter, 第4作者, 2020
- Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors, 第17作者, 2019
- Inhibition of the BET family reduces its new target gene IDO1 expression and the production of l -kynurenine, 第8作者, 2019
- New microtubulin inhibitor MT189 suppresses angiogenesis via the JNK-VEGF/VEGFR2 signaling axis, 第7作者, 2018
- Structural Modification of Natural Product Tanshinone I Leading to Discovery of Novel Nitrogen-Enriched Derivatives with Enhanced Anticancer Profile and Improved Drug-like Properties, 第6作者, 2018
- New tanshinone I derivatives S222 and S439 similarly inhibit topoisomerase I/II but reveal different p53-dependency in inducing G2/M arrest and
